Kinex Pharmaceuticals Receives $40,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1973f72f-9408-4ddc-9e4b-76436960571b - Date
3/6/2014 - Company Name
Kinex Pharmaceuticals - Mailing Address
701 Ellicott Street Buffalo, NY 14203 - Company Description
Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases. - Website
http://www.kinexpharma.com - Transaction Type
Venture Equity - Transaction Amount
$40,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds from this round, coupled with cash on hand, will be used to fund the completion of the commercialization of its oral form of paclitaxel (Oraxol) and irinotecan (Oratecan) in select markets outside of the United States. In addition, the proceeds will fund mid-stage clinical trials in the United States of four of eight Kinex drug candidates. - M&A Terms
- Venture Investor
Undisclosed
